No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 17 | 65 | 0 | 5 | N/A | N/A | N/A | N/A |
| Operating profit | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | $m | 1 | 10 | -0 | 9 | N/A | N/A | N/A | N/A |
| EPS reported | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | Locked | Locked | Locked |
| Environmental score | Locked | Locked | Locked |
| Social score | Locked | Locked | Locked |
| Governance score | Locked | Locked | Locked |
| Risk rating | Locked | Locked | Locked |
Company overview
Helo Corp. operates as a wellness technology firm, primarily focused on the "quantified-self" market through its range of wearable devices. These devices, along with their accompanying applications, enable users to gain health insights by meticulously tracking their personal data. Among its offerings is the VYVO Vista, which gathers information for analyzing resting and active heart rates, estimating blood pressure, monitoring breath rate and energy levels, and providing feedback on mood and sleep quality. The product line also features the VYVO Sense, a smartband equipped with 6-axis movement detection and an integrated electrocardiogram (ECG) sensor. For more in-depth monitoring, the company offers the VYVO Icon smartwatch. This device collects data that allows third parties to estimate parameters such as body fat percentage, visceral fat levels, muscle mass, and bone mass. It can also generate third-party representations of ECGs and continuously detect potential irregular heart rhythms, including atrial fibrillation (AFib) and other arrhythmias. Beyond wearables, Helo Corp. provides the VYVO Leggera, a smart weighing scale that measures body weight and incorporates a bio-impedance (BI) sensor to infer bone weight, visceral fat, and body mass index. Further extending its collection are the VYVO Vista+ and the VYVO Watch Lite, which boasts capabilities such as continuous AFib detection, mood and energy tracking, fall detection, SpO2 (blood oxygen) measurement, and sleep apnea detection. The VYVO Watch Lite SE builds on this with highly accurate body temperature readings, precise to ±0.1°C. Its advanced offering, the VYVO Watch Generation 2, delivers medical-grade measurements with enhanced accuracy for blood oxygen levels, vascular aging assessments, and ECGs. Helo Corp. distributes its products through a strategic partnership with VYVO HK Ltd. and its established global distribution network. The company, headquartered in San Francisco, California, was founded in 2010. It originally operated under the name World Technology Corp. before rebranding to Helo Corp. in October 2018.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Helo Corp. operates as a wellness technology firm, primarily focused on the "quantified-self" market through its range of wearable devices. These devices, along with their accompanying applications, enable users to gain health insights by meticulously tracking their personal data. Among its offerings is the VYVO Vista, which gathers information for analyzing resting and active heart rates, estimating blood pressure, monitoring breath rate and energy levels, and providing feedback on mood and sleep quality. The product line also features the VYVO Sense, a smartband equipped with 6-axis movement detection and an integrated electrocardiogram (ECG) sensor. For more in-depth monitoring, the company offers the VYVO Icon smartwatch. This device collects data that allows third parties to estimate parameters such as body fat percentage, visceral fat levels, muscle mass, and bone mass. It can also generate third-party representations of ECGs and continuously detect potential irregular heart rhythms, including atrial fibrillation (AFib) and other arrhythmias. Beyond wearables, Helo Corp. provides the VYVO Leggera, a smart weighing scale that measures body weight and incorporates a bio-impedance (BI) sensor to infer bone weight, visceral fat, and body mass index. Further extending its collection are the VYVO Vista+ and the VYVO Watch Lite, which boasts capabilities such as continuous AFib detection, mood and energy tracking, fall detection, SpO2 (blood oxygen) measurement, and sleep apnea detection. The VYVO Watch Lite SE builds on this with highly accurate body temperature readings, precise to ±0.1°C. Its advanced offering, the VYVO Watch Generation 2, delivers medical-grade measurements with enhanced accuracy for blood oxygen levels, vascular aging assessments, and ECGs. Helo Corp. distributes its products through a strategic partnership with VYVO HK Ltd. and its established global distribution network. The company, headquartered in San Francisco, California, was founded in 2010. It originally operated under the name World Technology Corp. before rebranding to Helo Corp. in October 2018.